FO
AIMT

FT Options’s Aimmune Therapeutics AIMT Stock Holding History

FT Options’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$84K Buy
+70,000
New +$1.51M 0.13% 108

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FT Options's AIMT Position: Q3 2017 in Review

FT Options opened a new position in Aimmune Therapeutics (AIMT) in Q3 2017: 23,100 shares worth $573K. The stake represents 0.86% of the portfolio and ranks #38 among its holdings.

100 funds tracked by Wall St. Rank hold AIMT as of Q3 2017.

  • FT Options held 23,100 shares of Aimmune Therapeutics worth $573K as of Q3 2017.
  • Aimmune Therapeutics was a new FT Options position in Q3 2017.
  • Aimmune Therapeutics made up 0.86% of FT Options's portfolio in Q3 2017, its #38 holding.
  • 100 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.